Physician profile
Cassandra Lee
NPI 1033950175
$3,311.11
in general payments reported to CMS, 2019-2025
33 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $780 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $508.52 | 2024 | Watchman Flx |
| Abbvie INC. | $299.33 | 2024-2025 | |
| Neurelis, INC. | $224.23 | 2024-2025 | Valtoco |
| Lundbeck LLC | $188.43 | 2024-2025 | Rexulti, Vyepti |
| Argenx US, INC. | $174.62 | 2024-2025 | Vyvgart Hytrulo |
| Ucb, INC. | $161.48 | 2024-2025 | Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $142.96 | 2025 | Ultomiris |
| Emd Serono, INC. | $142.79 | 2025 | Mavenclad |
| Eisai INC. | $134.28 | 2024-2025 | |
| Pfizer INC. | $130.68 | 2025 | |
| Biogen, INC. | $110.29 | 2025 | Leqembi, Skyclarys |
| Genentech USA, INC. | $108.83 | 2025 | Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $96.36 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $96.28 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.54 | 2025 | Hyqvia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $82.67 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $71.96 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $63.73 | 2025 | Wainua |
| Genzyme Corporation | $62.00 | 2025 | |
| Tanabe Pharma America, INC. | $56.07 | 2025 | Radicava |
| Amgen INC. | $49.88 | 2025 | Uplizna |
| Averitas Pharma INC. | $45.10 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $28.59 | 2025 | |
| Mallinckrodt Hospital Products INC. | $27.45 | 2025 | Acthar |
| Janssen Biotech, INC. | $27.04 | 2025 | |
| Springworks Therapeutics, INC. | $25.72 | 2025 | Gomekli |
| Ani Pharmaceuticals, INC. | $25.21 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.86 | 2025 | |
| Merz Pharmaceuticals, LLC | $24.50 | 2025 | Inbrija, Xeomin |
| Lilly USA, LLC | $23.91 | 2025 | Kisunla |
| W. L. Gore & Associates, INC. | $21.97 | 2025 | Gore Cardioform Septal Occluder |
| Neurocrine Biosciences, INC. | $21.87 | 2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $17.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.